Vyera Pharmaceuticals, LLC

Last Updated:
Case Status:
Pending
Federal Trade Commission and State of New York, Plaintiffs v. Vyera Pharmaceuticals, LLC, a Delaware limited liability corporation; Phoenixus AG, a Swiss for-profit corporation; Martin Shkreli, individually, as an owner and former director of Phoenixus AG, and as a former executive of Vyera Pharmaceuticals, LLC; and Kevin Mulleady, individually, as an owner and director of Phoenixus AG, and as a former executive of Vyera Pharmaceuticals, LLC; Defendants.
FTC Matter/File Number:

161 0001

Civil Action Number:

20-cv-00706

Federal Court:
Southern District of New York

Case Summary

The Federal Trade Commission has filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on January 27, 2020, in the U.S. District Court for the Southern District of New York.